Reading on the web. Open in the Thier app for the full interactive version, progress tracking, and XP.
Open

Hormone-Axis Peptides — CJC-1295, Ipamorelin, Tesamorelin

1-minute read 30 XP in app 6 cards

Nudge, don't replace

Unlike injectable growth hormone (hGH), growth hormone secretagogues work upstream — they prompt your pituitary to release its own GH in natural pulses. CJC-1295, ipamorelin, sermorelin, and tesamorelin are the main examples. The theory: physiological pulsatile release vs supraphysiological replacement.

Fact

Tesamorelin is the exception

Tesamorelin (a GHRH analogue) is FDA-approved — specifically for HIV-associated lipodystrophy. It's the only hormone-axis peptide with full regulatory approval and a clear indication. CJC-1295, ipamorelin, sermorelin are compounded or research-grade in the US.

FDA-approved for HIV lipodystrophy
Try in app

Match the peptide

Connect each hormone-axis peptide to its primary claim.

This step is hands-on. Open the Thier app to try the full interaction.
Insight

Why people are cautious

Raising GH and IGF-1 over baseline for years is not obviously a longevity move. In model organisms, lower IGF-1 signalling generally extends lifespan. Humans with growth-hormone deficiency live longer than average. "Feel better now" and "live longer" may pull in opposite directions for this category.

Fact

What to monitor — IGF-1 + glucose, every 3 months

If you're using a GH secretagogue, the practical safety check is IGF-1 quarterly: stay in the upper-quartile of age-adjusted reference, not above. Sustained IGF-1 above the age-quartile ceiling correlates with insulin resistance, fluid retention, joint pain, and at the extreme, an open question about cancer risk (mendelian-randomisation studies show higher lifelong IGF-1 → modestly elevated breast + colorectal + prostate cancer signal). Also monitor fasting glucose + HbA1c — GH is counter-regulatory to insulin, so secretagogues can nudge glucose upward in already-insulin-resistant users.

q3 mo IGF-1 + glucose check
Takeaway

Key Takeaway

Tesamorelin is the only FDA-approved member of this class. The others live in compounding + research-grade territory. The premise — more GH + IGF-1 = better longevity — is at odds with most of the long-life biology literature. If you're using one, monitor IGF-1 + glucose quarterly and stay in the upper-quartile of the age range, not above. Use with clear eyes.

References

  1. Tesamorelin for HIV-associated lipodystrophy — phase 3Falutz et al., 2007
  2. Reduced GH/IGF-1 signalling and extended lifespan in model organismsJunnila et al., 2009
  3. Mendelian randomisation — IGF-1 + cancer riskLarsson et al., 2020

Track your progress

Read the cards above, then mark this lesson complete to track your progress.
Open in app for XP
Up next

Sourcing, Safety & Regulation